Efficacy and Safety Comparison of S-1 and Capecitabine in Metastatic Colorectal Carcinoma: A Systematic Review and Meta-Analysis.

Cureus · 2025 · PMC12452046 · PMID 40988826

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

did not reach statistical significanceno p-value reported

S-1-based regimens showed a trend toward a higher ORR than capecitabine, with a pooled risk ratio of 1.14 (95% CI: 0.99-1.32; p = 0.07), though this difference did not reach statistical significance.

also in 39,255 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.